**Specifications Table**TableSubject area*Clinical Biochemistry*More specific subject area*Six sigma process improvement*Type of data*Tables and figures*How data was acquired*Making use of open database connectivity downloads from Instrument Manager (Data Innovations) middleware for tests analyzed on Architect c-series and i-series instruments (Abbott) were made; Manual timed activities using a stopwatch and observer.*Data format*Raw and analyzed*Experimental factors*Not Applicable*Experimental features*Six sigma process improvement strategy was applied to improve laboratory test auto-verification*Data source location*St. Clare's Mercy Hospital and Health Sciences Centre in St. John's; and Western Memorial Hospital in Corner Brook, Canada.*Data accessibility*Raw data is maintained with the corresponding author.*

**Value of the data**•Provides outline for Six Sigma process improvement design for auto-verification processes.•Provides benchmarks and metrics to monitor and assess auto-verification processes.•Describes test specific auto-verification parameters and consistency checks to achieve 90% auto-verification.•Provides brief notes to medical laboratory technologists and basic strategies to address delta check and extreme values held for manual review.

1. Data {#s0005}
=======

The data presented is from three clinical chemistry laboratories in Newfoundland and Labrador where Six Sigma process improvement methodology was used to improve the efficiency of autoverification (AV) processes affecting clinical chemistry and immunoassay tests. Data includes baseline data from all three laboratories (HSC-Health Science Centre; WMH-Western Memorial Hospital; and SCH-St. Clare's Mercy Hospital), test specific parameters for the new AV system, and other tools to assist with operation of the new AV program which achieved greater than 90% sample AV at the three sites examined. The original AV system is described, specific changes made, and some effects on the changes.

2. Experimental design, materials and methods {#s0010}
=============================================

A Six Sigma process improvement effort carried out to improve AV processes at the three sites \[[@bib1]\]. All sites had similar AV routines starting out. An outline of the Six Sigma process improvement schedule based on DMAIC (Design, Measure, Analyze, Improve, Control) methodology is provided in [Table 1](#t0005){ref-type="table"}. The project team consisted of thirteen-members representing managers, clinical biochemists, front line staff and others. The process metrics and benchmarks/targets were established during the "Design and Measurement" phases. Various process maps including [Fig. 1](#f0005){ref-type="fig"} which outlines the patient result verification workflow were also constructed to better understand the AV process. The reliability and reproducibility of all process metrics were validated and are listed in [Table 2](#t0010){ref-type="table"} along with baseline and benchmarks or targets for each metric. Baseline values for most metrics were mainly determined from download and analysis of test order specific information from Instrument manager (IM) middleware. An exception was test manual verification time which was determined by an observer who timed by stop watch the manual verification activities by medical laboratory technologists (MLTs) both during the Measurement Phase but also later during the Control phase. The new AV scheme (parameters detailed in [Supplementary Table 3](#s0025){ref-type="sec"}) was developed following review of process metrics and examination of the original system, and by several rounds of meetings with MLTs at the three sites in order to gain insight on manual verification activities. The key changes made and their predicted impact on test hold rates are summarized in [Table 3](#t0015){ref-type="table"}. The predicted impact of various rules and consistency checks on proportions of tests held for manual review and verification were evaluated using downloaded patient test results from the laboratory information system. A description of consistency check rules and calculations are summarized in [Table 4](#t0020){ref-type="table"} and the notes back to MLTs for each are summarized in [Table 5](#t0025){ref-type="table"}. Following implementation of the new AV system several new tools were implemented in order to allow continuous monitoring of the impact of the new system on error detection ([Fig. 2](#f0010){ref-type="fig"}) and in order to standardize evaluation of extreme values ([Fig. 3](#f0015){ref-type="fig"}A) and delta checks ([Fig. 3](#f0015){ref-type="fig"}B) to compliment the automated comments to MLTs concerning consistency checks and HIL failures. The impact of the new AV system compared to the original one relative to time spent by MLTs for review and release of held tests are summarized in [Table 6](#t0030){ref-type="table"}.Fig. 1Top level process map describing the AV work flow. This swim-lane diagram identifies actions done by the automated analyzer, the middle ware software (Instrument Manager), the MLT (or technologist), and laboratory/hospital information system (LIS/HIS).Fig. 1Fig. 2Post-improvement occurrence documentation form. Quality flags indicate consistency checks and various HIL flags.Fig. 2Fig. 3Decision tree for tests held as extreme results (A) and delta checks (B).Fig. 3Table 1Summary of activities by phase of the AV project.Table 1**PhaseDescriptionActivitiesRelative start time (Duration)Define**Most elements of project planning were carried out during this phase of the work.•Identify Sponsor(s)•Draft Project Charter•Draft & finalize Schedule•Select/Prepare project team•Construct top level process map•Construct top level SIPOC[a](#tbl1fna){ref-type="table-fn"} diagram•Identify metrics•Finalize Project CharterWeek 1 (2 weeks)**Measure**This phase involved defining, evaluating, and implementing a system for measuring the AV process.•Construct process maps for AV•Select metrics•Develop/Implement monitoring system•Begin data collection•Evaluate the measurement systemWeek 3 (10 weeks)**Analyze**This phase involved developing AV benchmarks and targets; and analyzing and interpreting data to inform decisions on improvements.•AV Value Stream Analysis•Determine AV benchmark•Perform AV variance analysis•Perform Root cause analysis•Analyze requirements and process drivers summarize analysesWeek 13 (2 weeks)**Improve**This phase involved development and implementation of new AV process.•Prioritize improvement opportunities•Design new AV process•FMEA[b](#tbl1fnb){ref-type="table-fn"} for new AV process•Implement new AV process•Examine early data from new process and optimize parameters•Feedback meetings with MLTsWeek 15 (8 weeks)**Control**This phase involved verification of improvements and development of a control plan to maintain the new AV process.•Confirm/validate new AV process•Develop and implement SOPs[c](#tbl1fnc){ref-type="table-fn"} and monitoring plan•Assign a monitor•Approve of deliverables•Project closeout and reviewWeek 23 (8 weeks)[^1][^2][^3]Table 2Summary of metrics and targets for the new AV system.Table 2***Performance metrics*****Definition/unitsBaselineBenchmark or target*****Samples Held***Proportion of samples analyzed per week.HSC: 0.398 ± 0.037 (*n* = 6)\< 0.10WMH: 0.650 ± 0.014(*n* = 6)SCH: 0.604 ± 0.036(*n* = 6)***Tests Held***Proportion of all tests analyzed per week.HSC: 0.225 ± 0.009 (*n* = 6)\< 0.10WMH: 0.209 ± 0.009(*n* = 6)SCH: 0.223 ± 0.012(*n* = 6)***Potassium Tests Held by HIL Flags***Proportion of all potassium tests per week.3.7%\< 2.5%***Potassium Tests Held by Delta Check***Proportion of all potassium tests per week.3.7%\< 2.5%***Potassium Tests Held by High/Low***[a](#tbl2fna){ref-type="table-fn"}Proportion of all potassium tests per week.12.8%\< 1%***Potassium Tests Held for Consistency Check***Proportion of all potassium tests per week.1.6%\< 2.5%***Process Time***Median time (minutes) from placement on track to result release to electronic medical record per week.HSC: 41.3 ± 1.00[b](#tbl2fnb){ref-type="table-fn"} (*n* = 6)≤ baselineWMH: 32.8 ± 1.2[b](#tbl2fnb){ref-type="table-fn"} (*n* = 7)***Total Time for Result Verification***Weekly labor time associated with review of tests held for manual review (calculated from the "Test Manual Verification Time" and average number of samples held per week).16,785 ± 5461 s\> 50% reduction***Test Manual Verification Time***Average time (seconds) spent reviewing held samples.7.1 ± 4.0 (Mean ± SD)≥ baseline[^4][^5]Table 3Pre-existing and predicted (for new AV process) proportion of tests held for manual review for AV components and consistency check rules. Frequency of tests being held and predicted rates are based on HSC data. Hold rates were determined by analyzing total tests held by criteria over a two week period from March 27 to April 10, 2017 and involving 80,876 tests from HSC. Similar data was also used to predict future AV hold rates for the new rules.Table 3**Result hold rulesProposedTest hold rate**[c](#tbl4fnc){ref-type="table-fn"}**Predicted rateDelta check**Use 0.025 and 0.975 percentiles to set limits.[a](#tbl4fna){ref-type="table-fn"}^,^[b](#tbl4fnb){ref-type="table-fn"}0.0128\< 0.005**Extreme values**Use 0.0025 and 0.9975 percentile estimates versus reference ranges0.1962\< 0.005**HIL flags**Hold only results that require action only.0.0102\< 0.0025**Critical values**Critical values will be maintained without modification0.0073\< 0.01**Consistency checksAnion gap**Less than 4 or greater than 200.0073No hold**BUN/creatinine ratio**NewNo hold**A/P ratio**New absurdity ruleNew\< 0.0001**Transaminase rule**[c](#tbl4fnc){ref-type="table-fn"}New rule based on 0.0025--0.0075 percentileNew\< 0.005**DB/TB Ratio**[c](#tbl4fnc){ref-type="table-fn"}New absurdity ruleNew\< 0.0001**Both TSH and fT4 \> upper reference limit**New rule for rare and unusual observations (secondary or tertiary hyperthyroidism)New\< 0.0005**Both TSH and fT4 \< lower reference limit**New rule for rare and unusual observations (secondary or tertiary hypothyroidism)New\< 0.0005**All indices (H, I, L) of ≥ 1+**New rule for poor sample quality (vendor)New\< 0.0001**hemolysis is ≥ 2+ and lipemia flag is ≥ 1+**New rule for poor sample quality (vendor)New\< 0.0001**hemolysis is 4+ and lipemia flag is ≥ 1+**New rule for poor sample quality (vendor)New\< 0.0001**Ictchk1 = Total bilirubin - \"I-index as concentration\"**New rule for interference in bilirubin assayNew\< 0.0001**Sodium \< 131, Chloride \< 105, Potassium \< 4.1 (Reflex Glucose \> 20** **mmol/L)**New rule to detect interference by dextrose solutionNew\~ 0.001**Sodium \< 132, Chloride \< 103, Potassium \< 4.1. Glucose \> 18**New rule to detect interference by dextrose solutionNew\< 0.0005**Sodium \< 126, Chloride \< 105, Potassium \< 3.8**New rule to detect interference by dextrose solutionNew\< 0.0005**Potassium \> 7 and (Calcium \< 2, or ALP \< 50, or Magnesium \< 0.5)**Existing rule to detect EDTA interference.0.0002\< 0.0005**HDL \> Chol**New absurdity ruleNew\< 0.0001**Anion Gap \< 1**New\< 0.0001[^6][^7][^8]Table 4Consistency check calculations and rule definition.Table 4**NumberTestCalculation/Logic**1BUN/Creat ratioBUN/Creat ratio = Urea/(Creatinine/1000) (Information rule only)2AGAG = Sodium - Chloride - Total CO2 (Information rule only)3DB/TB ratioDB/TB ratio = Direct Bilirubin/Total Bilirubin (\> 1 will flag)4A/P ratioA/P ratio = Albumin/Total Protein (beyond 0.25 or 1 will flag)5Transam ratioTransam ratio = ALT/AST (beyond 0.25 or 4 will flag)6T4 high ruleBoth TSH and fT4 greater than upper reference limit7T4 low ruleBoth TSH and fT4 less than lower reference limit8HIL all positiveAll indices (H, I, L) of one plus or greater.9H-L flag 1hemolysis is ≥ 2+ and lipemia flag is ≥ 1+10H-L flag 2hemolysis is 4+ and lipemia flag is ≥ 1+11IcterrorIctchk1 = Total bilirubin - \"I index as concentration\" (\> 65 will flag)12ContSamp1Sodium \< 130, Chloride \< 100, Potassium \> 5.513ContSamp2Sodium \< 131, Chloride \< 105, Potassium \< 4.1 (Reflex glucose \> 20 mmol/L)14ContSamp3Sodium \< 132, Chloride \< 103, Potassium \< 4.1. Glucose \> 1815ContSamp4Sodium \< 126, Chloride \< 105, Potassium \< 3.816IvgluSodium \< 136,Chloride \< 98, Potassium \> 5.5, Glucose \> 6.017IVglu2Negative delta for sodium and chloride and positive delta for glucose and potassium18IVsalinecont1Sodium \> 160, Chloride \> 110, Potassium \< 3.5, glucose \< 3.319Ivsalinecont2Positive delta for Sodium and Chloride and negative delta for glucose and potassium20EDTA CheckPotassium \> 7 and (Calcium \< 2, or ALP \< 50, or Magnesium \< 0.5)21Tchol-HDLTchol-HDL = HDL/Chol (\>0.75 will flag)22Delay CheckGlucose \< 2.21,Potassium \> 6, hemolysis index \< 50 or negative23Fibrin CheckSodium\< 136, Potassium \< 3.5, Calcium \< 2.1, Glucose \< 3.9 (and negative deltas)24Mixup1Delta calculation (((Current Creat -Past Creat)/Past Creat)/days)\*100% (beyond − 50% or + 50% will flag)25Mixup2Delta calculation ((Current Creat -Past Creat)/Past Creat)\*100% (beyond 50% will flag)26AGLowAnion Gap \< 1Table 5Notes to MLTs for consistency checks and HIL flags.Table 5Comment codeNote to MLTAGRuleRepeat electrolyte measurements unless patient previously had similarly abnormal anion gap. If not confirmed investigate for analytical errors affecting electrolytes. Unless sodium or albumin are low, very low anion gaps (\< 1) may be caused by analytical error.A-PruleRepeat albumin and total protein on a different instrument. Perform QC check. Contact physician/unit to discuss if required.BUN-CruleUse when unusual urea or creatinine results. Repeat BUN and creatinine on a different instruments. Perform QC check. Contact physician/unit to discuss if required. Normal ratio 40--100; \> 100 in prerenal failure; \< 40 intrinsic renal disease.ContSampSuppress all results, call ward and determine if sample collected from line. Contamination Risk!!!DB-TBRuleRepeat Direct and Total bilirubin on a different instrument. Perform QC check. Contact physician/unit to discuss if required.DelaychkPossible specimen delay error!!!. Examine collection time and investigate.DeltDetermine if result is expected. Contact physician/unit to discuss if necessary. If not expected, recommend recollection.EDTAchkExamine calcium, or magnesium, or ALP results for potential EDTA interference. (All will be very low!)FibrinchkPossible Fibrin error!!! Especially if accompanied by negative deltas. Inspect sample, re-centrifuge and reanalyze.HDLCHchkRepeat HDL and total cholesterol on a different instrument. Perform QC check. Contact physician/unit to discuss if required.Hem4+Inspect sample for gross hemolysis. If confirmed, report no result and recommend specimen recollection.HILallfailPossible indice error. Please visually inspect sample and verify all results if there are not sample quality concernsHLflag1Inspect sample for lipemia. Verify results if there are no sample quality concerns.HLflag2Inspect sample for lipemia and confirm sample has been centrifuged. Reject if sample has been centrifuged!IctInspect sample for icterus. If confirmed, report no result for test.IcterrorPossible paraprotein interference in bilirubin assay! Obtain the I-index value, repeat total bilirubin on a different analyzer, measure direct bilirubin, and correlate with SPE results. If SPE has monoclonal protein and \"Icterror\" confirmed, do not report bilirubin results - report possible paraprotein interference.LipInspect Sample. Ultracentrifuge and rerun all ordered chemistries (excluding lipids).T4RuleRepeat fT4 and TSH on a different instrument. Perform QC check. Contact physician to discuss if required.TransRuleRepeat AST and ALT on a different instrument. Perform QC check. Contact physician/unit to discuss if required.UHRammoniaCompare sample age with analysis time. Samples should be promptly analyzed \< 1 h of collection. Consult specimen test stability table.MixchkInvestigate specimen for mix-up. Correlate with changes in other tests and rule out renal failure and dialysis patients.UCRELNote very low urine creatinine! Correlate with serum creatinine and other tests.Table 6Average time for release of samples by MLTs during manual verification. Manual result verification time studies were conducted at HSC site by an observer using a stop watch and timing technologists as they went about manual review activities. Verification time was determined from point of first appearance of result profile to release of results to the electronic record. Appearance of critical results were sporadic but these time periods were removed as they were very variable in length, proportionately more common during the post-improvement stage, and tended to skew average time per sample verified.Table 6**MLTNumber of samplesSeconds per sampleNumber of samplesSeconds per sample1-SBPre-improvement**726.57**Post-improvement2-R**1237.83**3-W**2136.01**4-A**10016.588612.03**5-DC**2044.901118.00**6-AM**425.004531.91**7-K**1095.105815.76**8-Cas**1005.051319.62**9-L**729.29**10-N**2320.43**All**7.13 ± 3.9521.01 ± 7.15[\*](#tbl7fnStar){ref-type="table-fn"}[^9]
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[^1]: SIPOC (Suppliers, Inputs, Process, Outputs, Customers).

[^2]: FMEA (Failure Modes and Effects Analysis).

[^3]: SOP (Standard Operating Procedures).

[^4]: Outside of upper (High) and lower (Low) limit of normal.

[^5]: Based on time specimen on automated track system at HSC, but from time of receipt in the laboratory at WMH. Expressed as average weekly median and standard deviation.

[^6]: Park et al. [@bib2].

[^7]: Lee et al. [@bib3].

[^8]: New rules with no occurrence in the data set were assigned a predicted frequency \< 0.0001.

[^9]: Statistically significant based on *p* \< 0.001 by Student *T* test for independent samples.
